Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
Company hires life science veteran Jessica Cao to join management team
As per partnership, Carbanio will arrange raw materials and other custom chemicals for Proexp Pharma Pvt. Ltd. through an uninterrupted digital process of the company
The two-year agreement will grant Lonza access to IBF's prominent network and allow IBF to benefit from Lonza's manufacturing expertise and knowledge in its due diligence review of potential targets
New block enhances the company's global capabilities in Oral Solid Dosage (OSD) Forms, increasing total plant capacity to 4.5 billion doses
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
East Syracuse site to serve as the LOTTE Center for North America Operations for LOTTE’s biologics contract development and manufacturing organization (CDMO) business
Subscribe To Our Newsletter & Stay Updated
